AdvaMed, MDMA Take Issue With CMS’ New Tech Add-On Payment Policy
This article was originally published in The Gray Sheet
Executive Summary
CMS' proposed redefinition of "new" technologies contradicts Medicare statute, according to AdvaMed
You may also be interested in...
AdvaMed Provides CMS With New Technology Add-On Payment Wish List
AdvaMed is urging CMS to make its annual "town hall" meeting on new technology add-on payment submissions more interactive
AdvaMed Provides CMS With New Technology Add-On Payment Wish List
AdvaMed is urging CMS to make its annual "town hall" meeting on new technology add-on payment submissions more interactive
AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria
CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application